Navigation Links
BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
Date:5/1/2008

s for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, futur
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioMS Medical to present at EQUITIES Conference
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical to present at BioCentury Conference
4. BioMS Medical Announces 2007 Year End Results
5. BioMS Medical to present at BIO CEO & Investor Conference
6. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces third quarter 2007 results
10. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
11. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)... DuPont Applied BioSciences has turned to MBI ...g the commercial viability of an important bio-bas...bridging the gap between research and commercializ...d technologies. MBI’s unique “Collabor...resses technological uncertainties, which impede n...
(Date:12/2/2008)...c. 2 GeneGo, Inc., the leading sys...urnham has become a certified GeneGo Center of Exc...-wide access to GeneGo,s MetaCore data analysis su...nstitute is a world-class biomedical research faci...hroughout many departments, including research in ...
(Date:12/2/2008)...c. 2 Intradigm Corporation, a lead...nce (RNAi) therapeutics, today,announced the issu...Methods,and Compositions for Controlling Efficacy...based on the seminal research of Philip Zamore, Ph...Sciences and Professor of Biochemistry,& Mole...
(Date:12/2/2008)...ogy Earns an Innovation Point as a Stand-Alone Pro...ire/ -- The National Geographic Society has used a...to be re-certified as a national leader in energy ...e technology, manufactured by StrionAir of Louisvi...ree points for its LEED-EB 2.0* re-certification a...
Breaking Biology Technology: DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product 2The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 3National Geographic Uses Air Filtration in Bid To Be an Energy, Environmental Leader 2
...our-port Ethernet cards it began offering in Janu...ware for Apple G4 and G4 servers that combines Eth...more bandwidth. , ,The company is the first to pro...erve and Power Mac platforms. In March, it expande...ent Corky Seeber has designs on a market niche tha...
...s implemented IBM s eServer BladeCenter JS20 as t...rt system for proteomics research. IBM announced l...t blade system based on Power Architecture will b...he MCW is the initial customer site to test the Se...Sequest is an application specifically for use in ...
...that China represents phenomenal opportunities for...sconsin companies doing business in China and othe...protect their intellectual property and technology...icant counterfeiting still occurs, despite the eff... to prevent it. Therefore, Wisconsin companies sh...
...l technology subsidiary of Marshall & Ilsley Corpo...itive agreement to acquire the Kirchman Corporati...an Corporation is a provider of automation softwar... The Kirchman Corporation will become a Metavante ...ial Services Group. The transaction, terms of whic...
Other Biology Technology:Small Tree boosts bandwidth for Apple G4 and G5 servers 2Medical College of Wisconsin enhances research with IBM Blade server 2Protecting your intellectual property in overseas markets 2Metavante acquires Florida banking corporation 2
(Date:12/1/2008)...laboration of Stanford University,s Woods Institut...the World Wildlife Fundhas been awarded a two-year...ore Foundation to develop a software program for m...ed by temperate marine ecosystems. , Called Mari...ces and Tradeoffs), the proposed software will giv...
(Date:12/1/2008)...ne site of the journal Biology of Reproduction , ...ime that vitamin D induces immune responses in pla...timicrobial protein cathelicidin. , The study in...o the active form of vitamin D, leading to product... response in the trophoblast cells. , The team, ...
(Date:12/1/2008)...sity] Gray mold is a gardener,s nightmare. The fu...cinerea , is a scourge to more than 200 agricultur... such as tomatoes, strawberries, snap and lima bea...d potatoes. Gray mold envelops its target in a vel... plants, cells, eventually causing the plant to di...
(Date:12/1/2008)...ry" of sea and land animals around a group of Anta...diversity and has more species than the Galapagos....tor how they will respond to future environmental ... Biogeography , the team from British Antarctic Su...combed the land, sea and shores of the South Orkne...
Breaking Biology News(10 mins):Natural Capital Project to develop conservation software 2Brown chemist finds gray mold's killer gene 2Luminex Corporation Third Quarter Earnings Release Scheduled for October 24 2007 1184 1Luminex Corporation Third Quarter Earnings Release Scheduled for October 24 2007 1184 2Luminex Corporation Third Quarter Earnings Release Scheduled for October 24 2007 1184 3Low Lead Exposures Can Hurt Kidneys 3337 1Tooth loss dementia may be linked JADA study suggests 3335 1Microgrid allows simultaneous study of multiple variables 3333 1Microgrid allows simultaneous study of multiple variables 3333 2
...al vaccine can prevent mice from developing a brai... research that will be presented at the American A...n, April 28 ?May 5, 2007. Prion diseases, which in...g disease, are fatal and there is no treatment or ...he body parts of other animals contaminated with p...
...urally occurring molecule in the body appears to c...drenergic receptor agonists used in acute heart fa...iveness over time. , Nitric oxide is a molecule pr...ncluding the contraction or dilation of blood vess...sity Medical Center and Howard Hughes Medical Inst...
...a tree in your tank." Fuel companies aren,t toutin...esearch done in part by Bruce Dale, Michigan State...materials science, making fuels from poplar trees ...t-effective. , Dale is internationally known fo...plant biomass ?the stems, leaves, stalks and trunk...
...umble coral may possess as many genes ?and possibl...hough it is very distant from humans in evolutiona...hat protect people against disease. In fact, it is... , Corals are among the simplest animals in the ...e and complex as our own, says Professor David Mil...
Other Biology News:Vaccine prevents prion disease in mice 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3Corals -- More complex than you? 2Corals -- More complex than you? 3
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody.
4',6-Diamidino-2-phenylindole, dihydrochloride (DAPI)
Includes PROTEAN II xi Basic unit and IPG conversion kit PROTEAN II XL Cell, wide format, Compatible with ReadyStrip IPG Strips 1.0 mm 165-3188 1.5 mm 165-3189 2.0 mm 165-3190
The PROTEAN II xi cell, 16 cm, is used for vertical slab gel electrophoresis of nucleic acids and proteins in agarose gels. The cell is supplied without spacers and combs. The unit includes a central
Biology Products: